CN111991268A - Cosmetic matrix with skin repairing effect - Google Patents
Cosmetic matrix with skin repairing effect Download PDFInfo
- Publication number
- CN111991268A CN111991268A CN202010851666.3A CN202010851666A CN111991268A CN 111991268 A CN111991268 A CN 111991268A CN 202010851666 A CN202010851666 A CN 202010851666A CN 111991268 A CN111991268 A CN 111991268A
- Authority
- CN
- China
- Prior art keywords
- cosmetic
- skin
- parts
- repairing effect
- tripeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 239000011159 matrix material Substances 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- -1 astringent Substances 0.000 abstract description 4
- 239000012752 auxiliary agent Substances 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229920001503 Glucan Polymers 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012224 working solution Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 230000008439 repair process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a cosmetic matrix with skin repairing effect, which comprises the following components in parts by weight: 31-5 parts of oligopeptide; 11-5 parts of tripeptide-l; 10-20 parts of mannitol; 10-20 parts of trehalose; 10-20 parts of glucan; 15-25 parts of an auxiliary agent; the balance of water; the invention also relates to a method for preparing the cosmetic base; the invention further relates to a cosmetic with skin repairing efficacy; the cosmetic matrix with the skin repairing effect has the skin repairing effect, and can be prepared into different cosmetics such as astringent, lotion, cream and the like.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a cosmetic matrix with skin repairing effect.
Background
The stratum corneum layer of the skin surface is medically known as the skin barrier. The skin barrier can resist external harmful substances, irritants and sunlight, and has effects of keeping moisture and regulating antiinflammatory. The damage of skin physical barrier can cause skin dryness, skin aging, pigmentation atopic dermatitis, eczema, psoriasis, ichthyosis, skin sensitivity such as solar dermatitis, irritant dermatitis, hormone dependent dermatitis, etc., and seborrheic diseases such as acne, rosacea, seborrheic dermatitis, etc. At present, the demand for cosmetics with skin repair efficacy is increasing due to environmental and health concerns, but such cosmetics are not common in the market, so a cosmetic matrix with skin repair efficacy is urgently needed.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a cosmetic matrix with skin repair effect.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides a cosmetic matrix with skin repairing efficacy, which comprises the following components in parts by weight:
preferably, the component ratio of the oligopeptide-3 to the tripeptide-1 is 5:1-1: 5.
Further preferably, the ratio of the oligopeptide-3 to the tripeptide-1 is 1: 1.
Preferably, the total concentration of the oligopeptide-3 and the tripeptide-1 is 0.5-1.5 mg/mL.
Further preferably, the total concentration of the oligopeptide-3 and the tripeptide-1 is 1 mg/mL.
Preferably, the auxiliary agent comprises: one or more of a humectant, an anti-allergy agent, a gel thickener, a pH regulator, an emulsifier, a bactericidal preservative and a solubilizer.
A second aspect of the present invention provides a method for preparing a cosmetic base as described above, comprising the steps of:
mixing the components according to the weight ratio, and heating and stirring uniformly; filtering with microporous membrane for sterilization to obtain the cosmetic matrix.
In a third aspect of the invention, a cosmetic with skin repair efficacy is provided, which comprises the cosmetic matrix.
Preferably, the mass fraction of the cosmetic matrix in the cosmetic is 20-30%.
By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
the cosmetic matrix with the skin repairing effect has the skin repairing effect, and can be prepared into different cosmetics such as astringent, lotion, cream and the like.
Drawings
FIG. 1 is a graph of cell viability for assay example 1 of the present invention;
FIG. 2 shows the result of cytomorphological examination in examination example 1 of the present invention;
FIG. 3 shows the results of histomorphometry in example 2 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.
The invention is further described with reference to the following drawings and specific examples, which are not intended to be limiting.
Example 1
The embodiment provides a cosmetic matrix with skin repairing efficacy, which is prepared by mixing the following components in parts by weight:
wherein the total concentration of the oligopeptide-3 and the tripeptide-1 is 1 mg/mL; the auxiliary agent comprises: humectant, anti-allergic agent, gel thickener, pH regulator, emulsifier, antiseptic and solubilizer;
heating and stirring uniformly;
filtering with microporous membrane for sterilization to obtain the cosmetic matrix.
Detection example 1: cytotoxicity and morphology assays
1. Cell inoculation: by 1 × 104Cell/well seeding Density cells were plated onto 96-well plates in incubators (37, ° C5% CO)295% RH) overnight.
2. Grouping experiments: the experiment was set up with a zero adjustment group, a solvent control group, a positive control group and a sample group. In the sample set, 8 concentration gradients were set for each sample, and 3 replicate wells were set for each concentration gradient.
3. Preparing liquid: sample working solutions with different concentrations were prepared according to the test concentration setting table (table 1).
TABLE 1 test concentration setting Table
4. Administration: and (3) administration is carried out when the cell plating rate in the 96-well plate reaches 40-60%. Adding 200 mu L of culture solution into each well of the solvent control group; adding 200 mu L of culture solution containing 10% DMSO into each well of the positive control group; adding 200 mu L of culture solution containing samples with corresponding concentrations into each well of the sample group; the zero-adjusted group was seeded without cells, and only 200. mu.L of cell culture medium was added. After completion of the administration, the 96-well plate was placed in an incubator (37 ℃ C., 5% CO)295% RH).
5. And (3) detection: after 24h of cell incubation culture, the supernatant was discarded, MTT working solution (0.5mg/mL) was added, incubation was performed at 37 ℃ for 4h in the dark, after the incubation was completed, the supernatant was discarded, 150. mu.L of DMSO was added to each well, and OD was read at 490 nm.
6. Calculating the relative activity of the cells: the relative cell viability (%) was calculated according to the formula (sample well OD-zero well OD) ÷ (solvent control well OD-zero well OD) × 100%.
The detection results are shown in table 2, the relative cell viability curve is drawn by taking 8 concentrations selected by the cosmetic matrix of the sample as the abscissa and the relative cell viability value as the ordinate, and the cell viability change trend is shown in fig. 1.
Results of cytotoxicity assay of cosmetic base materials described in Table 2
Based on the MTT assay results, 5 concentrations with cell viability around 90% were selected for morphological examination (see table 3).
TABLE 3 morphometric assay concentrations
1. Cell inoculation: and (3) setting a sample group and a solvent control group, wherein each group is provided with two multiple holes. The cells were seeded at the corresponding seeding density in 24-well plates, incubators (37 ℃ C., 5% CO)295% RH) overnight.
2. Preparing liquid: according to the MTT detection result, determining the morphological observation concentration of the detection sample, and preparing the working solution of the test object with different concentrations.
3. Administration: when the cell plating rate of the 24-pore plate reaches 40%, the drug is administered, the samples are added with the test substances with different concentrations, the solvent contrast is added with the culture solution of keratinocyte and fibroblast, and the culture box (37 ℃, 5% CO)295% RH) for 24 h.
4. And (3) cell observation: after incubation, cell morphology was observed under a microscope and photographed.
The detection result is shown in figure 2, when the total concentration of oligopeptide-3 and tripeptide-1 in the cosmetic matrix of the sample is 1mg/mL, the relative activity value of the cell is 98.14%, and the cell state is not obviously different from that of a solvent control group. Therefore, according to the MTT results and the morphological results, no cytotoxicity was exhibited in the concentration range of 1 mg/mL.
Detection example 2: tissue morphology detection
1. Design of experiments
The experimental grouping was specifically set up as shown in table 4.
TABLE 4 experimental design
2. Sample preparation
2.10.4% SLS mother liquor preparation: 0.024g of SLS is weighed and dissolved in 6mL of PBS solution, and 0.22 μm of SLS solution is filtered to prepare 0.4 percent of SLS mother liquor for standby. Diluting the 0.4% SLS solution by 2 times to prepare 0.2% SLS working solution.
2.2 positive control group (WY14643) working solution formulation: weighing 10mg of WY14643 powder, dissolving in 1mL of DMSO, and preparing 30mM WY14643 mother liquor; mu.L of WY14643 stock solution (30mM) was added to 6mL of the model culture solution to prepare 50. mu.M of a working solution for use.
2.3 sample preparation of the cosmetic base working fluid: 10mg/mL sample the cosmetic base + 0.2% SLS: 1mL of 20mg/mL sample of the cosmetic matrix is put into a 5mL EP tube, and then 1mL of 0.4% SLS is added and mixed well for later use.
3. Experimental procedure
3.1 according to the experimental design of Table 4, the model was transferred to a 6-well plate (0.9 mL of model culture medium was added in advance) and the 6-well plate was marked with the test group number.
3.2 adding 25 μ L of the prepared working solution to the surface of the model, slightly shaking the model to uniformly distribute the sample on the surface of the model, and placing in CO2Incubator (37 ℃, 5% CO)295% RH) for 24 h.
3.3 after the incubation is finished, washing the residual test object on the surface of the model by using a washing bottle filled with sterile PBS solution, and slightly wiping the residual liquid inside and outside the model by using a sterile cotton swab.
4. Tissue morphology detection
Fixing the model for tissue morphology with 4% paraformaldehyde, fixing for 24H, cutting off the model, performing H & E staining, taking a picture under a microscope, and collecting the picture.
The detection results are shown in fig. 3, wherein a is the detection results of BC group model 1; the graph b is the detection result of the BC group model 2; FIG. c shows the results of detection of the BC group model 3; FIG. d is a view showing the result of detection of the NC group model 1; FIG. e is a view showing the result of detection by the NC group model 2; FIG. f shows the result of detection by the NC group model 3; FIG. g shows the results of the test of model 1 in the PC (i.e., WY14643) group; FIG. h shows the result of the test of the PC set model 2; FIG. i shows the test results of the PC group model 3; FIG. j is a graph showing the results of detection in the sample group model 1; FIG. k is a graph showing the results of measurement in the sample group model 2; FIG. l shows the results of the measurement in the sample group model 3.
The tissue morphology detection result shows that compared with the BC group, the NC group epidermal model has loose and thickened cuticle, damaged living cell layer and empty bubble, which indicates that the SLS stimulation condition is effective; compared with an NC group, the boundary of the four-layer structure of the PC group model is clear, the arrangement of cells of the living cell layer is compact, and the phenomenon of loose and thickened cuticle is obviously improved, which shows that the detection system is effective; compared with an NC group, the four-layer structure boundary of the group model is clear, the damage condition of a living cell layer is improved to a certain extent, and the phenomenon of cuticle loosening and thickening is relieved to a certain extent; therefore, the sample has certain repairing efficacy on 3D epidermis model morphological damage caused by SLS under the concentration of 10 mg/mL.
Example 2
This example provides a cosmetic product having skin rejuvenation benefits comprising the cosmetic base of example 1 in a mass fraction of 25%.
Detection example 4: trial effect detection
The test population: 10 adult female volunteers aged between 30-40 years;
the test method comprises the following steps: volunteers applied the cosmetic of example 2 to the face after cleansing the face in the morning and evening each day; the TEWL values were measured on the cheek area after 2 and 4 weeks of continuous use using a Tewameter TM300, the baseline TEWL being measured in a dry, non-sweaty skin condition at an ambient temperature of 21 deg., and an ambient humidity of 50%. TEWL reflects well the integrity of the skin barrier function, an increase in TEWL values, meaning an increase in skin moisture emission, and a decrease in TEWL values, in contrast, indicates that the barrier has been repaired.
The test results are shown in table 5.
TABLE 5 test results of effectiveness
In conclusion, the cosmetic matrix with skin repairing efficacy has skin repairing efficacy, and can be prepared into different cosmetics such as astringent, lotion, cream and the like.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (9)
1. The cosmetic matrix with the skin repairing effect is characterized by comprising the following components in parts by weight:
2. the cosmetic base according to claim 1, wherein the ratio of the oligopeptide-3 to the tripeptide-1 is 5:1 to 1: 5.
3. The cosmetic base according to claim 2, wherein the ratio of the oligopeptide-3 to the tripeptide-1 is 1: 1.
4. The cosmetic base according to claim 1, wherein the total concentration of oligopeptide-3 and tripeptide-1 is 0.5-1.5 mg/mL.
5. The cosmetic base according to claim 3, wherein the total concentration of oligopeptide-3 and tripeptide-1 is 1 mg/mL.
6. The cosmetic base of claim 1, wherein the adjunct comprises: one or more of a humectant, an anti-allergy agent, a gel thickener, a pH regulator, an emulsifier, a bactericidal preservative and a solubilizer.
7. A process for the preparation of a cosmetic base according to any one of claims 1 to 6, characterized in that it comprises the steps of:
mixing the components according to the weight ratio, and heating and stirring uniformly; filtering with microporous membrane for sterilization to obtain the cosmetic matrix.
8. A cosmetic preparation having skin-repairing effect, comprising the cosmetic base according to any one of claims 1 to 6.
9. The cosmetic according to claim 8, wherein the cosmetic base is present in the cosmetic in an amount of 20 to 30% by mass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851666.3A CN111991268A (en) | 2020-08-21 | 2020-08-21 | Cosmetic matrix with skin repairing effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851666.3A CN111991268A (en) | 2020-08-21 | 2020-08-21 | Cosmetic matrix with skin repairing effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111991268A true CN111991268A (en) | 2020-11-27 |
Family
ID=73473936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010851666.3A Pending CN111991268A (en) | 2020-08-21 | 2020-08-21 | Cosmetic matrix with skin repairing effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991268A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604704A (en) * | 2019-10-15 | 2019-12-24 | 广州启妆生物科技有限公司 | Peptide composition cosmetic and preparation method thereof |
| CN110638682A (en) * | 2019-11-01 | 2020-01-03 | 广州启妆生物科技有限公司 | Jiudai peptide composite freeze-dried powder and preparation method thereof |
| CN110882177A (en) * | 2019-12-19 | 2020-03-17 | 上海塔丽生物科技有限公司 | Skin repair oligopeptide composition and preparation method thereof |
-
2020
- 2020-08-21 CN CN202010851666.3A patent/CN111991268A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604704A (en) * | 2019-10-15 | 2019-12-24 | 广州启妆生物科技有限公司 | Peptide composition cosmetic and preparation method thereof |
| CN110638682A (en) * | 2019-11-01 | 2020-01-03 | 广州启妆生物科技有限公司 | Jiudai peptide composite freeze-dried powder and preparation method thereof |
| CN110882177A (en) * | 2019-12-19 | 2020-03-17 | 上海塔丽生物科技有限公司 | Skin repair oligopeptide composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 上海煦轼生物科技有限公司: ""T&O净痘清肤多肽修护面膜"", 《国产非特殊用途化妆品备案服务平台》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109865160B (en) | Lipid-like liquid crystal compound and preparation method thereof | |
| CN103330658B (en) | Skin care composition with functions of repairing damaged skin surface lipid film and relieving skin pressure | |
| CN105168008A (en) | Anti-wrinkle composition and external skin composition | |
| CN112315846A (en) | Schizophyllum commune polysaccharide liposome and preparation method and application thereof | |
| CN113304086A (en) | Multi-dimensional barrier repair composition and preparation method thereof | |
| CN110339078A (en) | It is a kind of to have effects that nourish the composition of maintenance skin and its application | |
| DE69131692T3 (en) | METHOD AND COMPOSITION FOR IMPROVING THE UNEFFECTIVE IMPACT OF AGING | |
| CN116350550A (en) | Face cream with moisturizing and soothing effects and preparation method thereof | |
| CN108498371B (en) | A kind of composition and preparation method thereof with reparation skin barrier effect | |
| DE69826547T2 (en) | Composition for extending the hair growth phase | |
| CN111991268A (en) | Cosmetic matrix with skin repairing effect | |
| CN107115220A (en) | A kind of activity of fighting against senium compositions and preparation method and application | |
| CN113318166A (en) | Plant composition and preparation method and application thereof | |
| CN115054566B (en) | Scalp aging resisting composition and preparation method thereof | |
| CN113940909B (en) | Composition for regulating circadian rhythm and application thereof | |
| KR20170010499A (en) | Cosmetic Compositions comprising Snail mucus fermentation filtrate for improving skin barrier function and having high skin absorption and Functional Cosmetic using this | |
| CN109381375A (en) | A kind of scalp care essential oil composition and application | |
| CN108403524A (en) | A kind of efficient spot-eliminating composition and its application | |
| CN104918605B (en) | Gel combination | |
| CN112933024A (en) | Repair face cream containing industrial hemp extract and preparation method thereof | |
| CN115813790B (en) | Shampoo capable of relieving and removing acnes | |
| CN115778872B (en) | Composition with acne removing and repairing effects, and preparation method and application thereof | |
| KR101373714B1 (en) | Cosmetic composition promoting cornified envelope formation | |
| EP2347797A2 (en) | Cosmetic method | |
| CN110013495A (en) | The composition for preventing and treating scytitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |
|
| RJ01 | Rejection of invention patent application after publication |